Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging

  • Rogowski-Lehmann, Natalie
  • Geroula, Aikaterini
  • Prejbisz, Aleksander
  • Timmers, Henri J L M
  • Megerle, Felix
  • Robledo Mercedes, Mercedes
  • Fassnacht, Martin
  • Fliedner, Stephanie
  • Reincke, Martin
  • Stell, Anthony
  • Januszewicz, Andrzej
  • Lenders, Jacques
  • Eisenhofer, Graeme
  • Beuschlein, Felix
CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are rare but potentially harmful tumors that can vary in their clinical presentation. Tumors may be found due to signs and symptoms, as part of a hereditary syndrome or following an imaging procedure. OBJECTIVE: To investigate potential differences in clinical presentation between PPGLs discovered by imaging (iPPGLs), symptomatic cases (sPPGLs) and those diagnosed during follow-up because of earlier disease/known hereditary mutations (fPPGL). DESIGN: Prospective study protocol, which has enrolled patients from 6 European centers with confirmed PPGLs. SETTING AND PATIENTS: Data were analyzed from 235 patients (37% iPPGLs, 36% sPPGLs, 27% fPPGLs) and compared for tumor volume, biochemical profile, mutation status, presence of metastases and self-reported symptoms. RESULTS: iPPGL patients were diagnosed at a significantly higher age than fPPGLs (p<0.001), found to have larger tumors (p=0.003) and higher metanephrine and normetanephrine levels at diagnosis (p=0.021). Significantly lower than in sPPGL, there was a relevant number of self-reported symptoms in iPPGL (2.9 vs. 4.3 symptoms, p<0.001). In 16.2% of iPPGL, mutations in susceptibility genes were detected, although this proportion was lower than in fPPGL (60.9%) and sPPGL (21.5%). CONCLUSIONS: Patients with PPGLs detected by imaging were older, have higher tumor volume and more excessive hormonal secretion in comparison to those found as part of a surveillance program. Presence of typical symptoms indicates that in a relevant proportion of those patients the PPGL diagnosis had been delayed. Précis: Pheochromocytoma/paraganglioma discovered by imaging are often symptomatic and carry a significant proportion of germline mutations in susceptibility genes.
Repisalud
Publication Artículo científico (JournalArticle)

Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma

  • Calsina, Bruna
  • Castro-Vega, Luis Jaime
  • Torres-Pérez, Rafael
  • Inglada Perez, Lucia
  • Currás-Freixes, Maria
  • Roldán-Romero, Juan María
  • Mancikova, Veronika
  • Letón, Rocío
  • Remacha, Laura
  • Santos, María
  • Burnichon, Nelly
  • Lussey-Lepoutre, Charlotte
  • Rapizzi, Elena
  • Graña, Osvaldo
  • Álvarez-Escolá, Cristina
  • de Cubas, Aguirre A
  • Lanillos, Javier
  • Cordero-Barreal, Alfonso
  • Martínez-Montes, Ángel M
  • Bellucci, Alexandre
  • Amar, Laurence
  • Fernandes-Rosa, Fabio Luiz
  • Calatayud, María
  • Aller, Javier
  • Lamas, Cristina
  • Sastre-Marcos, Júlia
  • Canu, Letizia
  • Korpershoek, Esther
  • Timmers, Henri J
  • Lenders, Jacques Wm
  • Beuschlein, Felix
  • Fassnacht-Capeller, Martin
  • Eisenhofer, Graeme
  • Mannelli, Massimo
  • Al-Shahrour, Fatima
  • Favier, Judith
  • Rodriguez Antona, Cristina
  • Cascon Soriano, Alberto
  • Montero-Conde, Cristina
  • Gimenez-Roqueplo, Anne-Paule
  • Robledo Mercedes, Mercedes
Rationale: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that present variable outcomes. To date, no effective therapies or reliable prognostic markers are available for patients who develop metastatic PPGL (mPPGL). Our aim was to discover robust prognostic markers validated through in vitro models, and define specific therapeutic options according to tumor genomic features. Methods: We analyzed three PPGL miRNome datasets (n=443), validated candidate markers and assessed them in serum samples (n=36) to find a metastatic miRNA signature. An integrative study of miRNome, transcriptome and proteome was performed to find miRNA targets, which were further characterized in vitro. Results: A signature of six miRNAs (miR-21-3p, miR-183-5p, miR-182-5p, miR-96-5p, miR-551b-3p, and miR-202-5p) was associated with metastatic risk and time to progression. A higher expression of five of these miRNAs was also detected in PPGL patients' liquid biopsies compared with controls. The combined expression of miR-21-3p/miR-183-5p showed the best power to predict metastasis (AUC=0.804, P=4.67·10-18), and was found associated in vitro with pro-metastatic features, such as neuroendocrine-mesenchymal transition phenotype, and increased cell migration rate. A pan-cancer multi-omic integrative study correlated miR-21-3p levels with TSC2 expression, mTOR pathway activation, and a predictive signature for mTOR inhibitor-sensitivity in PPGLs and other cancers. Likewise, we demonstrated in vitro a TSC2 repression and an enhanced rapamycin sensitivity upon miR-21-3p expression. Conclusions: Our findings support the assessment of miR-21-3p/miR-183-5p, in tumors and liquid biopsies, as biomarkers for risk stratification to improve the PPGL patients' management. We propose miR-21-3p to select mPPGL patients who may benefit from mTOR inhibitors.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X

  • Qin, Nan
  • Cubas, Aguirre A. de
  • García-Martín, Rubén
  • Richter, Susan
  • Peitzsch, Mirko
  • Menschikowski, Mario
  • Lenders, Jacques W. M.
  • Timmers, Henri J. L. M.
  • Mannelli, Massimo
  • Opocher, Giuseppe
  • Economopoulou, Matina
  • Siegert, Gabriele
  • Chavakis, Triantafyllos
  • Pacak, Karel
  • Robledo, Mercedes
  • Eisenhofer, Graeme
Deutsche Forschungsgemeinschaft (Microenvironment of the Adrenal); Grant number: EI 855/1-1, 252/0; Grant sponsor: European Union Seventh Framework Programme (Project ENS@T-Cancer); Grant number: FP7/2007–2013 (under grant agreement no. 259735); Grant sponsor: Fondo de Investigaciones Sanitarias; Grant number: Project PI11/01359; Grant sponsor: European Science Foundation (Research-Networking Program); Grant number: Reference 5925, Peer reviewed